fbpx Skip to main content

Research

Research is the key to ensuring children with cancer have the opportunity to thrive long beyond diagnosis. CURE’s research priorities are two-fold. First, we prioritize research that will lead to more effective treatments for children within two to three years. We also prioritize research aimed at solving recurrent and hard-to-treat cancers for which no effective treatment exists. Precision medicine, gene-based therapy, continues to be our highest priority, as we believe this approach to treatment shows extraordinary promise.

In response to CURE’s request for proposals, we received dozens of studies seeking funding. Our Peer Review Committee, comprised of expert oncologists and academic researchers, reviewed and scored each proposal using the same process employed by the National Institutes of Health. Their scores and critiques guided CURE’s board, ensuring we invest funds in the most strategic and prudent fashion.

We are proud to share that our 2022 research grants are focused almost entirely on helping children facing the toughest diagnoses – high-grade brain tumors, aggressive leukemias and solid tumors, and metastatic disease. These 18 grants awarded to top scientists at leading pediatric cancer research institutions across the nation total more than $4.7 million, CURE’s highest disbursement in a single grant cycle in our 47 year history.

Our 2022 Pediatric Cancer Research Initiative includes the following studies:

Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta

The Aflac Precision Medicine Program

Robert Castellino, MD
Combined molecular targeting to enhance therapy for group 3 medulloblastoma

Tobey MacDonald, MD 
Clinical investigation of cluster-wells in pediatric brain tumors

Christopher Porter, MD
Targeting mechanisms of T cell suppression mediated by Siglec15

Sunil Sudhir Raikar, MD 
Optimizing gamma delta T-cell immunotherapy for acute myeloid leukemia

Renee Read, PhD   
Human organoid models of pediatric high-grade gliomas

Muxiang Zhou, MD
Feasibility study of VERU-111 for precision treatment of pediatric AML

Beckman Research Institute of the City of Hope

Ling Li , PhD
Targeting PRMT1 elicits anti-tumor immunity in childhood leukemia

Qiang Lu, PhD
Developing inhibitors of mitotic kinesin KIF20A for brain tumor treatment

Children’s Hospital of Philadelphia

Michael Chorny, PhD 
Macromolecular prodrug-based therapy for indolent neuroblastoma

Timothy Olson, MD, PhD
Targeting niche inflammation and MSC cell fate in monosomy 7 predisposition

Vinodh Pillai, MD, PhD 
Assessment of bone marrow to predict response to CAR T-cell therapy

Indiana University

Jignesh Tailor, PhD
Discovery of synthetic lethal targets in MYCN neuroepithelial stem cells

Seattle Children’s Hospital

Elizabeth Lawlor, MD, PhD 
Optimizing safety and efficacy of anthracyclines in Ewing sarcoma

University Hospitals Rainbow Babies & Children’s Hospital

John Letterio, MD 
Development of a CNS-penetrant synthetic oleanane triterpenoid for DIPG

University of Texas Health Science Center at San Antonio

Raushan Kurmasheva, PhD 
PEGylated talazoparib for pediatric malignant rhabdoid tumor therapy

Virginia Polytechnic Institute and State University

Jia-Ray Yu, PhD 
Pharmacological screening of a new class of NSD1 inhibitor

Washington University in St. Louis

Jason Weber, PhD  
Development of p14ARF-based therapies to treat CDKN2A-deficient pediatric cancers

X